The history of the development of buprenorphine as an addiction therapeutic

  title={The history of the development of buprenorphine as an addiction therapeutic},
  author={Nancy D. Campbell and Anne M Lovell},
  journal={Annals of the New York Academy of Sciences},
This paper traces the early 21st century success of the agonist–antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social organization of laboratory‐based and clinical research within the domestic and international confluence of… 

Polluting pharmaceutical atmospheres: Compulsion, resistance, and symbolism of buprenorphine in Norway

It is shown that the social history of the medication is as significant as its pharmacological qualities for various treatment effects and the reciprocal shaping of lived experiences and institutional forces surrounding pharmaceutical use in general and opioids in particular.

Promise and Deceit: Pharmakos, Drug Replacement Therapy, and the Perils of Experience

  • Todd Meyers
  • Psychology, Medicine
    Culture, medicine and psychiatry
  • 2014
The paper demonstrates how the patient-subject comes to represent therapeutic promise by allowing for the possibility of (and often performing) deceit, in the context of opioid replacement therapy.

Medicalization and Biomedicalization: Does the Diseasing of Addiction Fit the Frame?

Purpose – The chapter examines the historical pattern of interconnections between drug policy, research, and treatment in light of recent theoretical developments in the medicalization thesis

Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan

This is the first grounded work in Asia that empirically examines and theoretically explains the diversion of B/N from an assemblage perspective and suggests establishing new associations by incorporating addiction treatment into NHI.

Influence of buprenorphine replacement therapy

It appears that there is less potential for drug abuse when buprenorphine is used instead of methadone, and social reintegration is an important aspect of social rehabilitation of opioid addicts, and it is therefore extremely important to recognize psychological and social factors that can act as protective factors, but also as risk factors.

Methadone and buprenorphine: The search for a non-addictive opioid

William Burroughs, a hugely influential post-modern American author, visual artist and member of the Beat generation, appeared in many recordings and films. He drew much of his inspiration from his

A Comparison of Suboxone and Methadone in the Treatment of Opiate Addiction

Suboxone and methadone are both proven to be effective treatment options for opiate addiction, and the research does not indicate that one medication is a better option than the other.

To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine.

It is argued that the therapeutics of buprenorphine govern patients and providers through this desire for freedom and normalcy, and is thus a technology of governmentality that extends neoliberal discourses and values and produces self-governing subjects.

New developments in managing opioid addiction: impact of a subdermal buprenorphine implant

The opioid abuse epidemic is introduced, existing medications used for therapy are examined, and Probuphine is highlighted as a new treatment option.



A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts

The results of this clinical trial indicated that buprenorphine was acceptable to patients and as effective as methadone in the detoxification treatment of heroin addicts.


  • D. Jasinski
  • Psychology, Medicine
    Annals of the New York Academy of Sciences
  • 1981
This presentation will summarize the highlight evolving concepts of the abstinence syndrome developed at the ARC and indicates the means for developing analgesics of lower abuse potential than morphine.

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.

A controlled trial of buprenorphine treatment for opioid dependence.

Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methad one, 20 mg/D, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks.


A group of 22 patients, previously addicted to diacetylmorphine (heroin), have been stabilized with oral methadone hydrochloride, and with this medication, patients have shown marked improvement; they have returned to school, obtained jobs, and have become reconciled with their families.

Human pharmacology of narcotic antagonists.

  • D. Jasinski
  • Biology, Medicine
    British journal of clinical pharmacology
  • 1979
1 Human studies at the Addiction Research Center enable narcotic antagonists to be classified into three subgroups: (1) nalorphine-like agents; (2) pure antagonists; and (3) morphine-like agents. 2

Tolerance and addiction liability of 6-dimethylamino-4-4-diphenylheptanone-3 (methadon).

The purpose of the present report is to summarize briefly the data collected to date and to present an opinion of the liability of the drug to cause addiction, and more detailed reports are to be published later.